Mineralys Therapeutics Inc [MLYS] stock is trading at $13.49, up 5.64%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MLYS shares have gain 8.01% over the last week, with a monthly amount glided 0.82%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on July 10, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, Goldman started tracking the stock with Buy rating on April 02, 2024, and set its price target to $30. On March 07, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $45 on March 07, 2023. Guggenheim initiated its recommendation with a Buy and recommended $32 as its price target on March 07, 2023. In a note dated March 07, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $40 on this stock.
Mineralys Therapeutics Inc [MLYS] stock has fluctuated between $6.38 and $16.91 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $13.49 at the most recent close of the market. An investor can expect a potential return of 122.39% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.56 and Total Capital is -0.71.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.61 points at the first support level, and at 11.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.28, and for the 2nd resistance point, it is at 15.07.
Ratios To Look Out For
For context, Mineralys Therapeutics Inc’s Current Ratio is 8.55. As well, the Quick Ratio is 8.55, while the Cash Ratio is 3.11.
Transactions by insiders
Recent insider trading involved Rodman David Malcom, Chief Medical Officer, that happened on Nov 11 ’24 when 5026.0 shares were sold. Officer, Rodman David Malcom completed a deal on Nov 11 ’24 to buy 5026.0 shares. Meanwhile, Chief Medical Officer Rodman David Malcom sold 25482.0 shares on Nov 06 ’24.
